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Alterations of Phosphodiesterases  
in Adrenocortical Tumors
Fady Hannah-Shmouni†, Fabio R. Faucz and Constantine A. Stratakis*
Program on Developmental Endocrinology and Genetics (PDEGEN), Section on Endocrinology and Genetics (SEGEN), 
National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA
Alterations in the cyclic (c)AMP-dependent signaling pathway have been implicated in 
the majority of benign adrenocortical tumors (ACTs) causing Cushing syndrome (CS). 
Phosphodiesterases (PDEs) are enzymes that regulate cyclic nucleotide levels, including 
cyclic adenosine monophosphate (cAMP). Inactivating mutations and other functional 
variants in PDE11A and PDE8B, two cAMP-binding PDEs, predispose to ACTs. The 
involvement of these two genes in ACTs was initially revealed by a genome-wide 
association study in patients with micronodular bilateral adrenocortical hyperplasia. 
Thereafter, PDE11A or PDE8B genetic variants have been found in other ACTs, including 
macronodular adrenocortical hyperplasias and cortisol-producing adenomas. In addi-
tion, downregulation of PDE11A expression and inactivating variants of the gene have 
been found in hereditary and sporadic testicular germ cell tumors, as well as in prostatic 
cancer. PDEs confer an increased risk of ACT formation probably through, primarily, 
their action on cAMP levels, but other actions might be possible. In this report, we 
review what is known to date about PDE11A and PDE8B and their involvement in the 
predisposition to ACTs.
Keywords: phosphodiesterases, adrenocortical tumors, adrenal hyperplasia, Cushing syndrome, genetics, 
Carney complex, cAMP
iNTRODUCTiON
The development and function of the endocrine system is highly dependent on second messengers 
in hormonal signaling. Advances in molecular and genetic studies and appreciation for the impact 
of second messengers on endocrine physiology and disease sparked important discoveries in signal 
pathway research especially over the past decades. The first second messenger to be identified was 
cyclic adenosine monophosphate (cAMP), described in 1958 by Earl Sutherland (1). The production 
and degradation of cAMP is regulated by adenyl cyclases (AC) and phosphodiesterases (PDEs), 
Abbreviations: AC, adenyl cyclase; ACTH, adrenocorticotropic hormone; AIMAH, ACTH-independent macronodular 
adrenal hyperplasia; AMP/ATP, adenosine monophosphate/adenosine triphosphate; Alleles, alternative forms of a gene; cAMP, 
cyclic adenosine monophosphate; CNC, Carney complex; CS, Cushing syndrome; CREB, cAMP-response element-binding 
protein; GMP/GDP/GTP, guanosine monophosphate/guanosine diphosphate/guanosine triphosphate; Genes, units of inherit-
ance at specific locations (loci) on a chromosome; GPCRs, G protein-coupled receptors; GWA, genome-wide association; 
heterozygous, a genotype with two different alleles of a gene for a particular trait; homozygous, a genotype with the same allele 
of a gene for a particular trait; MMAD, massive macronodular adrenocortical disease; mutations, alteration of genetic mate-
rial producing a new variation; PBAD, primary bimorphic adrenocortical disease; PBMAH, primary bilateral macronodular 
adrenocortical hyperplasia; PDEs, phosphodiesterases; phenotype, detectable expression of a genotype; PKA, protein kinase A; 
PPNAD, primary pigmented micronodular adrenal disease; PRKAR1A, protein kinase A regulatory subunit type 1.
FiGURe 1 | The cyclic AMP-dependent signaling pathway. G protein-coupled receptors (GPCRs) undergo conformational changes in response to various 
extracellular stimuli. Gsα subunit (G-proteins) exchanges GDP for GTP that activates adenylyl cyclase (AC), converting ATP to cAMP. Elevated cAMP levels, 
regulated by PDEs (also responsible for degradation of cGMP to GMP), then activate protein kinase A (PKA). PKA consists of a tetramer of two homo- or 
heterodimers regulatory subunits (R) and two catalytic subunits (C) responsible for the phosphorylation of several enzymes and transcription factors downstream 
[e.g., cAMP-response element-binding protein (CREB)]. The end product is gene expression to mediate cell growth and differentiation. Abbreviations: α, β, γ, 
Gs-protein subunits; AC, adenyl cyclase; C, catalytic subunit of protein kinase A; cAMP, cyclic AMP; CREB, cyclic AMP response element-binding protein, a 
transcription factor; GPCR, G-protein-coupled receptor; PDE, phosphodiesterase; PKA, protein kinase A; R, the regulatory subunits of protein kinase. Courtesy of 
Stratakis Lab, NICHD, NIH.
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respectively (Figure 1) (1, 2). Recent studies have demonstrated 
a link between genetic alterations in PDEs and increased predis-
position of tumor formation, particularly in the prostate, testis, 
and the adrenal cortex (3, 4). In primary bilateral macronodular 
adrenocortical hyperplasia (PBMAH), aberrant expression of 
several non-mutated G-protein-coupled receptors (GPCRs) 
showed that cAMP signaling could be increased without genetic 
mutations (5). In primary pigmented nodular adrenocortical 
disease (PPNAD), germline inactivating mutations of the protein 
kinase A regulatory subunit type 1 (PRKAR1A)-linked cAMP-
dependent protein kinase (PKA) to adrenocortical tumors (ACTs) 
(6). Indeed, cAMP signaling dysregulation through expression 
defects or mutations appears to underlie the pathogenesis of most 
benign ACTs (5, 7).
Phosphodiesterases exist in over 100 isoforms and are derived 
from 21 genes separated into 11 PDE gene families (summarized 
in Table 1) (8–10). PDEs function through the hydrolyzation of 
cAMP (PDEs isoform 4, 7, and 8) and cyclic guanosine monophos-
phate (cGMP) (PDEs isoforms 5, 6, and 9) into AMP and GMP, 
respectively (8, 9). Dual-specificity PDEs (acting on both cAMP 
and cGMP with varying affinities) include the PDE1, PDE2, PDE3, 
PDE10, and PDE11 enzymes. All PDEs share a major structural 
feature; a conserved catalytic domain with about 300 amino acids 
located near the C-terminal regions, and a variable regulatory 
domain located in the N-terminal regions. PDEs vary in a num-
ber of ways, including a difference in substrate selectivity, tissue 
distribution, kinetic, and tissue expression (Table 1). The adrenal 
cortex expresses several isoforms of PDEs, including PDE2A 
TABLe 1 | Characteristics of phosphodiesterases (PDes).
PDes Gene(s) Locus Substrate Major functions/regulations
PDE1 PDE1A
PDE1B
PDE1C
2q32.1
12q13.2
17p14.3
cAMP > cGMP
cAMP > cGMP
cAMP = cGMP
• Vascular smooth muscle contraction, sperm function
• Dopaminergic signaling, immune cell activation
• Vascular smooth muscle cell proliferation, sperm function
PDE2 PDE2A 11q13.4 cAMP = cGMP • Aldosterone and ACTH secretion, long-term memory
PDE3 PDE3A
PDE3B
12p12.2 cAMP > cGMP • Cardiac contractility, platelet aggregation, vascular smooth muscle contraction, oocyte 
maturation, and regulation of renin release
• Impact on lipolysis, glycogenolysis, insulin secretion, and cardiac function
11p15.2
PDE4 PDE4A 19p13.2 cAMP • Brain function, monocyte and macrophage activation, neutrophil infiltration, vascular smooth 
muscle proliferation, fertility
• Regulate β-adrenergic signaling and excitation–contraction coupling in the heart and thus play 
a role in vasodilatation and cardiac contractility
PDE4B 1p31.3
PDE4C 19p13.11
PDE4D 5q11.2–q12.1
PDE5 PDE5A 4q26 cGMP > cAMP • Modulate NO/cGMP effects in vascular smooth muscles, platelets, and lower urinary tract 
organs
• Cardiac stress response
PDE6 PDE6A 5q32 cGMP > cAMP • Primary effector enzyme in the phototransduction cascade
• Regulate cGMP concentration in rod and cone photoreceptorsPDE6B 4p16.3
PDE6C 10q23.33
PDE7 PDE7A 8q13.1 cAMP • Play a critical role in the regulation of the human T-cells function
PDE7B 6q23.3
PDE8 PDE8A 15q25.3 cAMP • Play a role in T-cell activation
• Regulate adrenal steroidogenesis
• Regulate TSH levels
• Control of LH signaling and steroidogenesis in Leydig cells
PDE8B 5q13.3
PDE9 PDE9A 21q22.3 cGMP > cAMP • Energy balance
PDE10 PDE10A 6q27 cAMP > cGMP • Play a role in striatal activation and behavioral activity
PDE11 PDE11A 2q31.2 cAMP = cGMP • Only the A4 splice variant is expressed in adrenal tissue
• Sperm production
ACTH, adrenocorticotropic hormone; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanine monophosphate; LH, luteinizing hormone; PDE11A, phosphodiesterase 11A 
gene; NO, nitric oxide; TSH, thyroid-stimulating hormone.
Adapted from Ref. (10).
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that has been implicated in the downregulation of aldosterone 
production in adrenal zona glomerulosa cells and the regulation 
of the adrenocorticotropic hormone (ACTH)-induced increase in 
intracellular cAMP in the zona fasciculata cells (11).
Recent studies have demonstrated inactivating mutations and 
other germline variants in PDE11A and PDE8B in ACT causing 
Cushing syndrome (CS) (12–17). Here, we present a brief over-
view of the alterations of PDEs in ACTs. Given the breadth of this 
topic, we begin with a discussion of the cAMP-dependent signal-
ing pathway in physiology, describe the current classification of 
ACTs, and then proceed with a discussion of PDE alterations in 
ACTs.
THe cAMP-DePeNDeNT SiGNALiNG 
PATHwAY
Briefly, GPCRs undergo conformational changes in response to 
various extracellular stimuli, such as ACTH (Figure 1). The first 
step in cAMP activation in adrenal cortex is the action of ACTH 
on its seven-transmembrane receptor, ACTHR [e.g., melano-
cortin 2 receptor (MC2R)]. This activation leads to the dissocia-
tion of the Gsα subunit (encoded by the GNAS gene) from the 
heterotrimeric G-proteins, activation of AC, generation of cAMP, 
and activating PKA (Figure 1). PKA exists as a tetrameric com-
plex of two regulatory subunits (alpha and beta type 1 or alpha 
and beta type 2, encoded by PRKAR1A, PRKAR2A, PRKAR1B, 
and PRKAR2B) and two catalytic subunits (catalytic alpha and 
catalytic beta, encoded by PRKACA and PRKACB, respectively); 
the latter subunits are responsible for the phosphorylation of 
several enzymes and transcription factors downstream, includ-
ing the cAMP-response element-binding protein (CREB). 
Abnormalities in some of these genes predispose to the forma-
tion of cortisol-producing ACTs (Figure 2) and increased steroid 
hormone secretion. The latter is often mediated by secondary fac-
tors regulated by PKA; in one study, silencing p54(nrb)/NONO 
expression in H295R human adrenocortical cells decreased the 
ability of the cells to increase intracellular cAMP production and 
subsequent cortisol biosynthesis in response to ACTH (18). The 
expression of multiple PDE isoforms, including PDE2A, PDE3A, 
PDE3B, PDE4A, PDE4D, and PDE11A, was induced in p54(nrb)/
NONO knockdown cells, which suggests that these proteins may 
be responsible for the splicing and degradation of PDE transcripts 
(18). Studies in knockout mice (Table 2) have also pointed out 
to the significance of cAMP signaling-regulating genes in ACT 
formation.
TABLe 2 | Adrenocortical phosphodiesterases mouse models and 
phenotypes.
Gene Model Phenotype
PDE2 Pde2atm1Dgen Homozygous for knockout allele exhibit lethality 
early in gestation therefore difficult to study (58)Pde2atm1Dtst
PDE8 Pde8btm1Dgen Homozygous for null allele with increased 
urine corticosterone, decreased serum ACTH, 
and decreased sensitivity to a PDE8-selective 
inhibitor (39)
PDE11 Pde11atm1Lex No adrenal phenotype. Homozygous for null allele 
have reduced sperm concentration (45)
FiGURe 2 | Aberrations in the cyclic AMP-dependent signaling pathway in adrenocortical tumors. Mutations such as activating mutations of GNAS, in 
McCune–Albright syndrome; inactivating germline mutations in PDE11A in primary pigmented nodular adrenocortical hyperplasia (PPNAD); and inactivating germline 
mutations of PRKAR1A in Carney’s complex, all predispose to the formation of adrenocortical tumors through a cyclic AMP-dependent process. Abbreviations: α, β, 
γ, Gs-protein subunits; AC, adenyl cyclase; ACA, adrenocortical adenoma; C, catalytic subunit of protein kinase A; cAMP, cyclic AMP; CREB, cyclic AMP response 
element-binding protein, a transcription factor; GPCR, G-protein-coupled receptor; PBMAH, bilateral macronodular adrenocortical hyperplasia; PDE, 
phosphodiesterase; PKA, protein kinase A; R, the regulatory subunits of protein kinase; PPNAD, primary pigmented nodular adrenocortical disease. Courtesy of 
Stratakis Lab, NICHD, NIH. 
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A HiSTORiCAL PeRSPeCTive AND 
NOMeNCLATURe OF ADReNOCORTiCAL 
TUMORS
In 1912, Cushing described the pituitary tumors that cause the 
condition that today bears his name (19). The causes of CS are 
broadly divided into ACTH-dependent and ACTH-independent 
disease. In 1984, the first description of Carney complex, a multi-
ple neoplasia syndrome associated with spotty skin pigmentation, 
cardiac myxomas, pituitary tumors, and CS caused by PPNAD, 
provided the first insight into the genetic forms of ACT (20). 
In 1991, Weinstein et  al. (21) described Gsα subunit (GNAS) 
mutations in individuals with McCune-Albright syndrome 
(MAS); MAS is classically associated with polyostotic fibrous 
dysplasia, café-au-lait skin spots, and precocious puberty but 
also with adrenal hyperplasia and/or tumors (21). MAS, albeit 
rare, appears to be the most frequent cause of CS among ACTH-
independent adrenal hyperplasia in the infantile period (22). 
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Kirschner et al. (23, 24) identified the regulatory subunit type 1A 
(R1α) of PKA (encoded by the PRKAR1A gene on chromosome 
17q22-24) as the cause of PPNAD and CNC (25). PPNAD is the 
most frequent endocrine manifestation in CNC.
In 2006, the first association between PDE mutations and ACT, 
using a genome-wide association (GWA) study approach, was 
identified in patients with CS with PPNAD but without GNAS 
or PRKAR1A mutations (12). Three inactivating mutations in 
PDE11A were identified initially in patients, predominantly 
children, with micronodular adrenocortical hyperplasia (iMAD), 
a rare form of bilateral adrenocortical hyperplasia (BAH) leading 
to CS. Subsequent studies found other PDE mutations or func-
tional variants, including alterations in PDE8B, in other ACTs, 
including PBMAH (14–17, 26, 27).
The new genetic findings influenced the diagnostic classifica-
tion of these ACTs (5). In brief, three major ACTH-independent 
ACT subtypes exist: bilateral hyperplasias (BAH), adrenocorti-
cal adenomas (ACA), and adrenocortical cancer (ACC) (5). 
PBMAH, a form of BAH, is estimated to affect ~2% of patients 
with endogenous CS (5). This disease should be distinguished 
from secondary adrenocortical hyperplasia, which can occur 
after long-term stimulation by ACTH in Cushing disease (CS in 
the context of an ACTH-producing pituitary tumor) or ectopic 
ACTH secretion, predominantly from a neuroendocrine tumor 
(28). PBMAH is usually sporadic, but familial forms have been 
described (29). Cortisol-producing adenoma (CPA) is a benign 
subset of ACAs causing adrenal CS.
Bilateral adrenocortical hyperplasias can be broadly 
classified on the basis of the size of their nodules into micro-
nodular (<1  cm in diameter) or macrocronodular (>1  cm 
in diameter) (5). The micronodular subtype is divided into 
pigmented (c-PPNAD, familial seen in CNC, or isolated, 
i-PPNAD) and not pigmented (e.g., iMAD) (5). PBMAH is the 
most common macronodular BAH [previously referred to as 
massive macronodular adrenocortical disease (MMAD) and 
ACTH-independent macronodular adrenocortical hyperplasia 
(AIMAH)] and is largely caused by mutations of the ARMC5 
gene (30); several genes have been implicated in other forms of 
macronodular BAH, including GNAS, APC, and MEN1. Patients 
with MAS may develop a form of macronodular bilateral 
adrenal hyperplasia, called primary bimorphic adrenocortical 
disease (PBAD).
PDes iN ADReNOCORTiCAL TUMORS
Mutations and variants in ACTs that lead to functional abnor-
malities of cAMP signaling have been reported in the GNAS, 
PRKAR1A, PDE11A, and PDE8B genes (9). Mutation-negative 
disease with activation of the cAMP pathway has been reported 
(31), suggesting that additional genetic (or perhaps epigenetic) 
“hits” may play a role in the pathogenesis of ACT.
PDe2A
The predominant PDE isoform in adrenal tissue is PDE2A (32). 
Three PDE2A isoforms exist: PDE2A1, PDE2A2, and PDE2A3, 
and exhibit higher affinity for cGMP than cAMP (33). PDE2A 
is implicated in the downregulation of aldosterone production 
in adrenal zona glomerulosa cells and the regulation of the 
ACTH-induced increase in intracellular cAMP (11). This ACTH 
response is described as a rapid and sustained activation of AC 
followed by a biphasic effect of ACTH on PDE2 activity with 
an initial and rapid inhibition, followed by a delayed activa-
tion (11). In one study, PDE2 involvement was observed to 
be more important in rat than in human adrenal glomerulosa 
cells, whereas AC was more stimulated in human than in rat 
glomerulosa cells (34). Thus, PDE2 activity is involved in the 
regulation of cAMP accumulation induced by ACTH and 
suggests that ACTH inhibits this activity. However, no studies 
to date have reported an association between alterations in 
PDE2 and ACTs. PDE2A has been shown to be upregulated in 
beta-catenin (CTNNB1)-mutated ACTs (35). However, it has 
not been studied in individuals with PPNAD that also have 
somatic mutations in CTNNB1 (36, 37). Importantly, Pde2a 
knockout mice do not survive past 17–18 days gestation (38); 
Pde2a heterozygote mice are not known to develop ACTs or 
even hypertension.
PDe8
The PDE8 family of proteins includes two genes, PDE8A and 
PDE8B, which encode for two highly specific enzymes respon-
sible for the highest affinity of the PDEs to degrade cAMP (32). 
Through negative modulation, these isomers play an important 
role in adrenal, ovarian, and testicular steroidogenesis (32, 39). 
Although homologous in structure and function, PDE8B is the 
major regulator of one or more pools of cAMP in steroidogen-
esis and carries the highest expression across zona fasciculata 
compared to other PDEs (14, 32, 39). PDE8A is expressed from 
a small population of zona fasciculata cells that lie adjacent to 
zona glomerulosa (32), while PDE8B is expressed throughout 
the zona fasciculata. The PDE8B locus, like that of other PDEs, 
is quite complex and encodes multiple isoforms, arising mainly 
from alternative splicing and displaying tissue-specific expression 
(32, 40, 41). Tsai et al. (39) demonstrated that Pde8b knockout 
mice showed elevated urinary corticosterone as a result of adrenal 
hypersensitivity toward ACTH (39), pointing to PDE8B’s possible 
role in regulating steroidogenesis. However, the investigators also 
demonstrated that these mice do not develop adrenal hyperplasia 
or increased adrenal size.
A GWA study identified a link between the 5q13 locus harbor-
ing the PDE8B gene and iMAD (12). A novel missense mutation 
was found in PDE8B (c.914A > C, p.P305H) in a 2-year-old girl 
with iMAD where her father carried the same genetic defect with 
subclinical disease (15); this pattern of an unaffected male passing 
on the disease to an affected female was also seen in other altera-
tions of PDEs (12, 42). The p.P305H mutation led to higher levels 
of cAMP when introduced in HEK293 cells (15).
A more recent study of ACTs found several variations in 
PDE8B: missense substitutions p.H391A, p.P660L, and p.V697I 
and the c.1365-5G>A splice variant in PDE8B were identified 
(43). Interestingly, one patient with ACC had both the mis-
sense p.R121H and the splice c.1365-5G>A variations, while 
the other germline PDE8B mutations were found in samples 
including PBMAH, PPNAD, and secreting and even non-
secreting ACAs (43).
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Perhaps, the most important recent finding confirming 
PDE8B’s role in ACT pathogenesis was the genome-wide tran-
scriptomic work by Wilmot Roussel et al. (44). Among over 3000 
genes that showed correlation with cortisol secretion in 22 uni-
lateral ACAs (5 non-secreting, 6 subclinical cortisol producing, 
and 11 cortisol producing), PDE8B showed the strongest positive 
correlation (44). Accordingly, there was marked increase of the 
PKA activity to cAMP ratio in secreting adenomas compared to 
non-secreting adenomas (44).
PDe11A
PDE11A is located on chromosome 2q31.2 and encodes a dual-
specificity PDE that degrades both cAMP and cGMP (32). This 
gene is highly polymorphic in the general population (42) and 
was the first of the PDEs to be linked with an inherited condition 
associated with ACTs. Four different transcript variants exist 
(Table  1), with only the PDE11A4 detected in adrenal tissues 
(32). Pde11a knockout mice show impaired sperm function 
and spermatogenesis (45), but no adrenal phenotype has been 
described for the knock out or heterozygote mouse. Several stud-
ies have reported conflicting results with regard to the adrenal 
expression of PDE11A, suggesting that its expression may only 
be driven in the diseased adrenal gland (46, 47). The exact role of 
PDE11A in regulating adrenocortical cAMP levels also remains 
largely unknown.
Horvath et al. (12) published the first GWA single-nucleotide 
polymorphism (SNP) association between PDE11A mutations 
and ACTs in patients with CS from PPNAD or iMAD without 
known genetic defects (12). Three inactivating mutations in 
PDE11A were identified. These tumors showed 2q31–2q35 loss of 
heterozygosity (LOH) and elevated cAMP levels (12), supporting 
PDE11A’s role in tumor formation. Three of the four patients had 
PPNAD; a mother and her daughter with the same PDE11A gene 
mutation, and a third unrelated patient with a different PDE11A 
mutation, in which the adrenal glands were described as small 
(largest total adrenal weight = 6.9 g and normal = 8–9 g) with 
very minor involvement of the superficial cortex evidenced by 
a few transcapsular cortical extensions into the peri-adrenal fat 
(48). The fourth patient’s adrenal glands were slightly enlarged 
owing to hyperplasia of the superficial cortex with a few PPNAD-
type nodules in the deep cortex (48). The PDE11A mutation was 
inherited from her father who had an enlarged right adrenal 
gland but no CS (48).
In another study, Horvath et al. (42) examined two relatively 
frequent variants of PDE11A in ACTs and the general popula-
tion (42). Twelve of 745 controls had these variants, with a lower 
frequency in patients with ACTs (1.6%; χ2 = 14.62, P < 0.0001). 
In vitro data demonstrated elevated cAMP levels in HeLa and 
HEK293 cells, particularly when the p.R804H mutation was 
studied (42). Another study showed the p.R867G PDE11A gene 
variant in one patient with familial PBMAH (49). The mechanism 
by which partially inactivated PDE11A causes adrenocortical 
overgrowth is largely unclear; the most likely explanation is 
chronic (albeit modest) elevations of cAMP levels in adrenocorti-
cal tissues. Collectively, these experiments suggest that genetic 
variations in PDE11A may be low-penetrance alleles that occur 
relatively frequently in the general population and may predis-
pose to the development of ACTs.
The association of PDE11A variants and ACTs was studied 
further in larger cohorts. Libé et al. (27) examined the role of the 
PDE11A in a large cohort of ACT, and found an inactivating muta-
tion (p.R307*) in one ACC, with a significant difference between 
ACC and controls for a polymorphism in exon 6 (p.E421E; OR, 
2.1; P = 0.03) (27). Three associated polymorphisms located in 
intron 10–exon 11–intron 11 were also significant in these tumors 
(OR, 0.5; P = 0.01) (27). Other variants in the study included 22 
germline missense variants (18.8%) in ACA, compared to only 
11 missense variants (5.7%) in controls (16 versus 10% in ACC, 
19 versus 10% in ACA, and 24 versus 9% in PBMAH; OR, 3.53; 
P = 0.05) (27). This study suggested a higher frequency of muta-
tions in ACTs, especially PBMAH, when compared to controls. 
In another study that examined a large cohort of patients with 
PBMAH, the frequency of all PDE11A variants (e.g., p.D609N or 
p.M878V) was significantly higher among patients with PBMAH 
(28%) than controls (7.2%) (P = 5 × 10−5) (17). These variants 
were also studied in HEK293 cells, where the mutant PDE11A-
transfected cells had higher cAMP levels than the wild-type ones 
(P <  0.05), suggesting that these mutants exhibit diminished 
cAMP hydrolytic activity (17).
These experiments pointed to several important points about 
the possible PDE11A’s role in adrenocortical tumorigenesis. First, 
the spectrum of ACTs varies from benign to malignant. Second, 
bilateral disease is favored. Third, the allelic losses of the wild-type 
allele in ACC with missense mutations supports PDE11A role 
as a tumor suppressor gene. Fourth, PDE11A sequence defects 
may underlie at least part of the commonly found adrenocortical 
incidentalomas.
Alterations in PDEs may also be involved in modifying the 
expression of syndromic diseases associated with ACTs. CNC is 
caused by PRKAR1A mutations, as discussed earlier (23). In one 
study of 150 patients with CNC, a higher frequency of PDE11A 
variants was observed when compared with healthy controls 
(25.3 versus 6.8%, P < 0.0001), particularly in men (30.8 versus 
13%, P = 0.025, PPNAD subgroup) (16). Importantly, these men 
had a higher incidence of large-cell calcifying Sertoli cell tumors, 
as well (16). Moreover, simultaneous in  vitro inactivation of 
PRKAR1A and PDE11A by small inhibitory RNA led to increased 
PKA activity and/or cAMP signaling (16). Thus, it is conceivable 
that PDE11A-inactivating variants act in concert with other genes 
in disease predisposition and/or progression.
ABeRRATiONS iN THe cAMP-
DePeNDeNT SiGNALiNG PATHwAY iN 
CORTiSOL-PRODUCiNG ADeNOMAS
Several genetic aberrations in the cAMP-dependent signaling 
pathway have been implicated in CPA. The most common genetic 
aberration in CPA is a somatic-activating mutations of PRKACA 
(c.617A>G/p.L206R) with an estimated incidence of ~42% (86 
of 206 tumors studied to date) (50–52), with a predilection to 
younger patients with overt CS, suggesting a driver mutation role 
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in tumorigenesis (44). Somatic mutations in GNAS were identi-
fied in 5–17% of CPA (53). The somatic allelic losses of PRKAR1A 
were described in 23% of CPA; these tumors were smaller in size 
and had a paradoxical increase in urinary cortisol levels after 
dexamethasone suppression (54), due to increased glucocorticoid 
receptor expression in ACT (55), as often observed in patients 
with c-PPNAD. Defects in Wnt-signaling have been reported 
in CPA, with CTNNB1 (p.S45P, p.S45F) in ~23% of cases (56). 
There are still many unknown genetic defects that lead to CPA 
formation.
FUTURe DiReCTiONS
There has been significant progress in PDE-related research 
over the past two decades. Genetic testing has uncovered several 
adrenocortical conditions that were linked to aberrations in PDE, 
often preceded by a long and insidious pre-diagnostic course. 
This has allowed earlier identification and better management of 
these lesions. However, there are several unanswered questions. 
PDE-related research is hampered by inherent (i.e., complexity 
of their structures, many intracellular interactions, and largely 
unknown function) and technical issues (e.g., there is lack of 
specific antibodies for the multiple isoform of each PDE). In addi-
tion to improving the characterization of PDE expression and 
function, future studies should also focus on the characterization 
of patients with various ACT phenotypes and PDE genotypes.
Preliminary results in using recombinant compounds to activate 
or inhibit the PDE11A structure may have important implications 
for drug development. Jäger et  al. (47) produced approximately 
fourfold to fivefold increase in PDE11A-mediated hydrolysis of 
both cAMP and cGMP, with some degree of PDE11A specificity, 
with a cGMP analog (Rp-8-pCPTPET-cGMPS) bound to the 
PDE11A4 GAF domain (47). Furthermore, Ceyhan et  al. (57) 
showed that BC11-28 and BC11-38 (potent and selective PDE11A 
inhibitors) in both yeast-based and enzyme assays had a >350-fold 
selectivity for inhibiting PDE11’s cGMP hydrolytic activity versus 
all other PDEs, while only BC11-38 inhibited PDE11A cAMP 
hydrolytic activity in H295R cells (57). Thus, a targeted molecular 
therapy approach for lesions related to defects in PDE may aid in 
the future management of affected or at risk patients.
CONCLUSiON
Alterations in PDEs that lead to dysregulation of the cAMP-
dependent signaling pathway have been linked to the develop-
ment of ACT. These lesions are usually benign and represent an 
important group of genetic disorders causing CS. As genetic tech-
nology continues to revolutionize the field of endocrine genetics 
and as we continue to discover novel disease-causing genes on 
an unprecedented scale, new methods to rapidly assess the func-
tional significance of PDE variants singly, or in combination, will 
evolve. In this review, we focused our discussion on the various 
genotypes and phenotypes of ACT due to alterations in PDE, 
particularly mutations in PDE8B and PDE11A. Although there 
has been significant progress in PDE-related research over the 
past two decades, there are as yet unidentified molecular causes 
for all of these lesions. We hope that one day targeted molecular 
therapies will replace adrenalectomy as the treatment of choice 
for these lesions.
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